Health Affairs, 24, no. 3 (2005): 631-634
doi: 10.1377/hlthaff.24.3.631
© 2005 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (5)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Plotkin, S. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Plotkin, S. A.
Related Collections
* Health Promotion/Disease Prevention
* International Issues
* Pharmaceuticals
* Public Health
* Research And Technology
* Consumer Issues
* Vaccines

Infrastructure

PERSPECTIVE

Why Certain Vaccines Have Been Delayed Or Not Developed At All

Stanley A. Plotkin

Vaccine development is a long process, with the time from early research to licensure steadily increasing. At one time the process took about ten years; now it takes closer to fifteen to twenty years. The process begins with investigators in universities or biotech firms who have an idea. However, to take things further, there must be a vaccine manufacturer, a regulatory authority ready to give permission for the use of the vaccine, and public health authorities that will recommend and foster vaccination.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Sci Transl MedHome page
R. Fears, J. W. M. van der Meer, and V. ter Meulen
Translational Medicine Policy Issues in Infectious Disease
Science Translational Medicine, January 13, 2010; 2(14): 14cm2 - 14cm2.
[Full Text] [PDF]


Home page
PediatricsHome page
A. K. Shen, L. E. Rodewald, and G. S. Birkhead
Perspective of Vaccine Manufacturers on Financing Pediatric and Adolescent Vaccines in the United States
Pediatrics, December 1, 2009; 124(Supplement_5): S540 - S547.
[Abstract] [Full Text] [PDF]